ITVI940170A1 - ALTERNATIVE USE OF THE O- (B-IDROSSIETIL) -RUTOSIDEA MOLECULE. - Google Patents
ALTERNATIVE USE OF THE O- (B-IDROSSIETIL) -RUTOSIDEA MOLECULE. Download PDFInfo
- Publication number
- ITVI940170A1 ITVI940170A1 IT94VI000170A ITVI940170A ITVI940170A1 IT VI940170 A1 ITVI940170 A1 IT VI940170A1 IT 94VI000170 A IT94VI000170 A IT 94VI000170A IT VI940170 A ITVI940170 A IT VI940170A IT VI940170 A1 ITVI940170 A1 IT VI940170A1
- Authority
- IT
- Italy
- Prior art keywords
- molecule
- hydroxyethyl
- rutosidea
- drug
- idrossietil
- Prior art date
Links
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 206010046996 Varicose vein Diseases 0.000 claims abstract description 4
- 230000032683 aging Effects 0.000 claims abstract description 4
- 208000027185 varicose disease Diseases 0.000 claims abstract description 4
- 229960004555 rutoside Drugs 0.000 claims description 5
- -1 β-hydroxyethyl Chemical group 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000007170 pathology Effects 0.000 description 2
- 241001262617 Japonica Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invenzione ha per oggetto un secondo uso della molecola 0-(B-idrossietil)-rutosidea, normalmente usata come farmaco emereologico nella cura delle varici, come ritardante dei fenomeni di invecchiamento. La molecola può essere usata da sola o in associazione ad altri farmaci di sostegno.The invention relates to a second use of the 0- (B-hydroxyethyl) -rutosidea molecule, normally used as an hemereological drug in the treatment of varicose veins, as a retarder of aging phenomena. The molecule can be used alone or in combination with other support drugs.
Description
D E S C R I Z I O N E DESCRIPTION
La presente invenzione ha per oggetto un nuovo uso di un preparato medico di cui è noto l'impiego in campo farmaceutico. The present invention relates to a new use of a medical preparation which is known to be used in the pharmaceutical field.
Il preparato medico in questione è la molecola di 0- (β-idrossietil) -rutosidea, che è un particolare estratto o derivato dalla pianta Sofora Japonica. The medical preparation in question is the molecule of 0- (β-hydroxyethyl) -rutoside, which is a particular extract or derivative from the plant Sofora Japonica.
E' noto che questa molecola è stata specificamente studiata e messa a punto come farmaco emereologico nella cura delle varici. It is known that this molecule has been specifically studied and developed as a hemeological drug in the treatment of varicose veins.
Non era noto a tutt'oggi un uso diverso di questa molecola per la cura di altre patologie o affezioni. It was not known to date a different use of this molecule for the treatment of other pathologies or affections.
Alcune ricerche condotte dal richiedente hanno messo però in rilievo un risultato straordinario ed assolutamente imprevedibile alla luce delle normali indicazioni fornite dal produttore del farmaco. However, some research conducted by the applicant highlighted an extraordinary and absolutely unpredictable result in the light of the normal indications provided by the drug manufacturer.
Infatti, è stato rilevato che la molecola di 0- (β-idrossietil) -rutosidea, se assunta con regolarità ed indipendentemente dalle patologie flebologiche, è capace di rallentare i naturali processi di invecchiamento . In fact, it has been found that the 0- (β-hydroxyethyl) -rutosid molecule, if taken regularly and regardless of phlebological pathologies, is capable of slowing down the natural aging processes.
In particolare i pazienti oggetto di osservazi hanno presentato un aspetto fisico più giovanile ed una maggiore motricità e scioltezza nei movimenti. In particular, the patients under observation showed a more youthful physical appearance and greater motor skills and ease of movement.
Il farmaco è stato sperimentato con successo su un campione di 10 pazienti di età compresa tra i 50 ed i 100 anni, in un arco temporale compreso tra 2 e 5 anni. In un solo caso questo periodo é stato prolungato per ben 15 anni. The drug was successfully tested on a sample of 10 patients aged between 50 and 100 years, over a period of between 2 and 5 years. In only one case this period was extended for a good 15 years.
Ai pazienti sono state somministrate, sotto assiduo controllo medico, dosi giornaliere che ammontano, in una prima fase di attacco, ad 1 grammo e in una seconda fase di mantenimento a 500 milligrammi. Patients were given, under constant medical supervision, daily doses that amount, in a first phase of attack, to 1 gram and in a second maintenance phase to 500 milligrams.
Il farmaco in queste dosi non ha presentato alcun effetto collaterale, mantenendo comunque inalterato il livello di efficacia per l'uso primario per il quale era stato inizialmente messo a punto. The drug in these doses did not present any side effects, however maintaining the level of efficacy for the primary use for which it was initially developed unaltered.
E' stato inoltre osservato che il farmaco in oggetto può essere vantaggiosamente associato ad altri principi attivi o farmaci di sostegno, quali ad esempio cerebro-attivi . It has also been observed that the drug in question can be advantageously associated with other active principles or supporting drugs, such as for example cerebro-active.
Dopo un attento esame, tutti i soggetti sottoposti a trattamento sistematico hanno dimostrato un aspetto fisico più giovanile rispetto ad altri della stessa età sottoposti a nessuno trattamento o a trattamento saltuario. E' stato particolarmente notato un notevole miglioramento della motricità specie nei pazienti a più prolungato trattamento. After careful examination, all subjects undergoing systematic treatment showed a more youthful physical appearance than others of the same age undergoing no treatment or occasional treatment. A notable improvement in motor skills was particularly noted, especially in patients with more prolonged treatment.
Da quanto sopra, deriva che la molecola O-(B-idrossietil)-rutosidea, normalmente usata come farmaco nella terapia delle varici, presenta un secondo uso alternativo come ritardante dei fenomeni di invecchiamento del quale si chiede una tutela specifica, sia nell'assunzione da solo che in associazione con altri farmaci e principi attivi. From the above, it follows that the molecule O- (B-hydroxyethyl) -rutoside, normally used as a drug in the therapy of varicose veins, has a second alternative use as a retarder of aging phenomena for which specific protection is required, both in the assumption alone or in association with other drugs and active ingredients.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT94VI000170A IT1267882B1 (en) | 1994-11-24 | 1994-11-24 | Alternative use of the O-(β-hydroxyethyl)rutoside molecule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT94VI000170A IT1267882B1 (en) | 1994-11-24 | 1994-11-24 | Alternative use of the O-(β-hydroxyethyl)rutoside molecule |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITVI940170A0 ITVI940170A0 (en) | 1994-11-24 |
| ITVI940170A1 true ITVI940170A1 (en) | 1996-05-24 |
| IT1267882B1 IT1267882B1 (en) | 1997-02-18 |
Family
ID=11425614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT94VI000170A IT1267882B1 (en) | 1994-11-24 | 1994-11-24 | Alternative use of the O-(β-hydroxyethyl)rutoside molecule |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT1267882B1 (en) |
-
1994
- 1994-11-24 IT IT94VI000170A patent/IT1267882B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IT1267882B1 (en) | 1997-02-18 |
| ITVI940170A0 (en) | 1994-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102141081B1 (en) | Composition for skin cell anti-inflammation or skin whitening | |
| Bhat et al. | Aloe vera: Nature's soothing healer to periodontal disease | |
| AU2002317053B2 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
| RU2283098C2 (en) | Coenzyme q-containing cutaneous compositions as active component | |
| US20100080768A1 (en) | Compositions and Methods for the Treatment of Inflammatory Dermatosis and Other Pathological Conditions of the Skin | |
| AU2310200A (en) | Pharmaceutical compositions | |
| TR199800258T1 (en) | New opioid peptides. | |
| WO1999059580A1 (en) | Preventives/remedies for skin diseases | |
| WO2016002767A1 (en) | Composition for external application | |
| TR200103153T2 (en) | New combinations | |
| ES2157005T3 (en) | USE OF BOSWELLICO ACID AND ITS DERIVATIVES FOR THE INHIBITION OF THE NORMAL AND ELEVATED ACTIVITY OF ELASTASA DE LEUCOCITOS OR PLASMINA. | |
| KR970061244A (en) | Pharmaceutical composition for treating dementia | |
| KR910005858A (en) | Fatty acid therapy | |
| Diebschlag et al. | A double‐blind study of the efficacy of topical ketorolac tromethamine gel in the treatment of ankle sprain, in comparison to placebo and etofenamate | |
| JPH0778011B2 (en) | Therapeutic agent that reduces seborrhea | |
| Vestergaard et al. | Lithium treatment of Huntington's chorea: A Placebo‐Controlled Clinical Trial | |
| KR102587300B1 (en) | A composition for preventing or treating for atopic dermatitis | |
| ITVI940170A1 (en) | ALTERNATIVE USE OF THE O- (B-IDROSSIETIL) -RUTOSIDEA MOLECULE. | |
| KR19990036233A (en) | Cosmetic methods to treat and prevent the symptoms of skin aging | |
| RU2475230C1 (en) | Therapeutic sunburn product | |
| KR20160091315A (en) | Multidrug-resistant gram-positive bacteria antibacterial agent and topical agent | |
| JPH06128136A (en) | Skin external preparation | |
| KR20150045420A (en) | Composition for blocking AGEs production comprising Akebia quinata extracts | |
| JPWO2019189742A1 (en) | Topical composition containing ascorbic acid and / or a salt thereof | |
| KR20140115742A (en) | Composition for blocking AGEs production comprising Akebia quinata extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted | ||
| TA | Fee payment date (situation as of event date), data collected since 19931001 |
Effective date: 19971127 |